At the 61st Suzhou API Fair, which ended recently, despite all parties optimistic about the impact of the financial crisis on the Chinese pharmaceutical industry, they believe that the rigid demand for pharmaceutical products in the world makes “the scenery is good†but the facts From the perspective of the Canton Fair concluded in late October, the sharp drop in pharmaceutical export orders is an indisputable fact. At the same time, the industry’s prediction that exports of Chinese pharmaceutical products in 2009 will continue to be suppressed by the international market has also become a lingering haze.
On November 18th, the signing ceremony of the Strategic Alliance for Antibiotics and Vitamin Industry Technology Innovation (hereinafter referred to as the Innovation Alliance) led by Shijiazhuang Pharmaceutical Group and Huabei Pharmaceutical Group was held in Beijing China Biotechnology Development Center. The two innovation alliances established under the promotion and support of the Ministry of Science and Technology of the People's Republic of China and the People's Government of Hebei Province, for the first time in 20 years after China’s large-scale raw material medicines have relied on economies of scale, low-cost strategies, will be the first to improve the competitiveness of the market. Progress, and the Ministry of Science and Technology invested nearly 200 million yuan. Although this kind of innovation alliance for the pharmaceutical industry, which is mainly for the first time, has an exploratory nature, the industry believes that the innovation alliance will lead the industry to form a technological synergy, and this industry transformation is necessary at the moment of the financial turmoil.
Four-volt market crisis
It is understood that some bulk API companies currently do not have a clear sense of the financial crisis. For example, Shijiazhuang Pharmaceutical Group, the profits in the first 10 months of this year have approached 1 billion yuan, and the number of foreign orders has not declined. In this regard, people in the industry believe that bulk APIs are the most intensive areas in the Chinese pharmaceutical industry. The leading enterprises in China, such as Huayao, Shiyao, Lukang and Harbin Pharmaceuticals, have the largest share of production capacity and exports in the country and have the right to speak in the international market. With the global demand for pharmaceutical products, the financial crisis has had little impact on the demand for APIs.
As we all know, the high concentration of bulk APIs is the result of a rational return after more than ten years of industrial disorderly expansion and vicious competition in the market. Today, with the appreciation of the renminbi, the prices of power, energy, and raw and auxiliary materials have risen sharply, labor costs have risen, and under the influence of objective factors of huge environmental pressure, the promotion of the pharmaceutical industry by means of labor-intensive and economies of scale reduction costs has reached its limit.
In the recent period, the huge price gap between domestic drugs and foreign drugs has once again become the focus of attention in the industry. It is learned that the National Development and Reform Commission is also planning to reform drug prices. According to Zhang Heming, head of the office of the Shijiazhuang Group, the ceftriaxone produced by the stone drug costs more than RMB 2 each, while the same dose of ceftriaxone sold by Roche sells for RMB 93.
Although the high spread of scores of times has been widely criticized by domestic enterprises, because many joint ventures or foreign companies' raw materials are imported from foreign countries at high prices, the profits displayed are not high—this practice of leaving high profits abroad has been Become an open secret in the pharmaceutical industry.
Tsinghua University’s International Technology Transfer Center’s right-to-business manager said that measuring whether an industry is strong depends on its profitability. The raw material medicine industry in China is a typical model with large scale but weak profitability. At the core technical level of cephalosporin production, there is indeed a gap between domestic and foreign-funded enterprises.
Build technology synergy
At the signing ceremony of the Innovation Alliance, 27 companies with strong advantages in the fields of antibiotics and vitamins, scientific research institutes, and higher education institutions solemnly signed their own names. A brand-new mode of technological innovation in production, research, and research emerged during the special period.
Promote industrial upgrading
"The exploration of such a cluster innovation mechanism can greatly promote industrial agglomeration and play a guiding role in the realization of large-scale cooperation and large-scale cooperation in production, research, and research, and provide a mechanism for the integration of antibiotic and vitamin industry clusters into the global industrial value chain." Yu Jianuo, vice president of East China University of Science and Technology, said.
According to Gan Rongfu, senior industry researcher of the Operation Management Department of Sinopharm Holdings Co., Ltd., the industry’s technological innovation brought about by the investment of 200 million yuan by the Ministry of Science and Technology and the industrial technology alliance led by large enterprises must be far-reaching. The development trend of the industry is to scale and intensify. Based on the current situation in China, the formation of synergy through technology is a powerful weapon for integrating into global competition and fighting the financial turmoil.
On November 18th, the signing ceremony of the Strategic Alliance for Antibiotics and Vitamin Industry Technology Innovation (hereinafter referred to as the Innovation Alliance) led by Shijiazhuang Pharmaceutical Group and Huabei Pharmaceutical Group was held in Beijing China Biotechnology Development Center. The two innovation alliances established under the promotion and support of the Ministry of Science and Technology of the People's Republic of China and the People's Government of Hebei Province, for the first time in 20 years after China’s large-scale raw material medicines have relied on economies of scale, low-cost strategies, will be the first to improve the competitiveness of the market. Progress, and the Ministry of Science and Technology invested nearly 200 million yuan. Although this kind of innovation alliance for the pharmaceutical industry, which is mainly for the first time, has an exploratory nature, the industry believes that the innovation alliance will lead the industry to form a technological synergy, and this industry transformation is necessary at the moment of the financial turmoil.
Four-volt market crisis
It is understood that some bulk API companies currently do not have a clear sense of the financial crisis. For example, Shijiazhuang Pharmaceutical Group, the profits in the first 10 months of this year have approached 1 billion yuan, and the number of foreign orders has not declined. In this regard, people in the industry believe that bulk APIs are the most intensive areas in the Chinese pharmaceutical industry. The leading enterprises in China, such as Huayao, Shiyao, Lukang and Harbin Pharmaceuticals, have the largest share of production capacity and exports in the country and have the right to speak in the international market. With the global demand for pharmaceutical products, the financial crisis has had little impact on the demand for APIs.
As we all know, the high concentration of bulk APIs is the result of a rational return after more than ten years of industrial disorderly expansion and vicious competition in the market. Today, with the appreciation of the renminbi, the prices of power, energy, and raw and auxiliary materials have risen sharply, labor costs have risen, and under the influence of objective factors of huge environmental pressure, the promotion of the pharmaceutical industry by means of labor-intensive and economies of scale reduction costs has reached its limit.
In the recent period, the huge price gap between domestic drugs and foreign drugs has once again become the focus of attention in the industry. It is learned that the National Development and Reform Commission is also planning to reform drug prices. According to Zhang Heming, head of the office of the Shijiazhuang Group, the ceftriaxone produced by the stone drug costs more than RMB 2 each, while the same dose of ceftriaxone sold by Roche sells for RMB 93.
Although the high spread of scores of times has been widely criticized by domestic enterprises, because many joint ventures or foreign companies' raw materials are imported from foreign countries at high prices, the profits displayed are not high—this practice of leaving high profits abroad has been Become an open secret in the pharmaceutical industry.
Tsinghua University’s International Technology Transfer Center’s right-to-business manager said that measuring whether an industry is strong depends on its profitability. The raw material medicine industry in China is a typical model with large scale but weak profitability. At the core technical level of cephalosporin production, there is indeed a gap between domestic and foreign-funded enterprises.
Build technology synergy
At the signing ceremony of the Innovation Alliance, 27 companies with strong advantages in the fields of antibiotics and vitamins, scientific research institutes, and higher education institutions solemnly signed their own names. A brand-new mode of technological innovation in production, research, and research emerged during the special period.
Promote industrial upgrading
"The exploration of such a cluster innovation mechanism can greatly promote industrial agglomeration and play a guiding role in the realization of large-scale cooperation and large-scale cooperation in production, research, and research, and provide a mechanism for the integration of antibiotic and vitamin industry clusters into the global industrial value chain." Yu Jianuo, vice president of East China University of Science and Technology, said.
According to Gan Rongfu, senior industry researcher of the Operation Management Department of Sinopharm Holdings Co., Ltd., the industry’s technological innovation brought about by the investment of 200 million yuan by the Ministry of Science and Technology and the industrial technology alliance led by large enterprises must be far-reaching. The development trend of the industry is to scale and intensify. Based on the current situation in China, the formation of synergy through technology is a powerful weapon for integrating into global competition and fighting the financial turmoil.
Calcium carbide is an inorganic substance, the chemical formula is CaC2, the main component of calcium carbide, white crystals, industrial products are gray-black lumps, and the cross section is purple or gray. It reacts violently when encountering water, generating acetylene and releasing heat. Calcium carbide is an important basic chemical raw material, mainly used to produce acetylene gas. Also used in organic synthesis, oxyacetylene welding, etc.
Acetylene produced by the reaction of calcium carbide with water can synthesize many organic compounds such as synthetic rubber, synthetic resin, acetone, ketene, carbon black, etc.; at the same time, acetylene-oxygen flame is widely used in metal welding and cutting.
Store in a cool, dry and well-ventilated warehouse. Keep away from fire and heat sources. The relative humidity is kept below 75%. The packaging must be sealed and protected from moisture. It should be stored separately from acids and alcohols, and avoid mixed storage. The storage area should be equipped with suitable materials to contain the leakage.
Calcium Carbide,Calcium Carbide 50-80mm,Calcium Carbide 100kg Drum,Calcium Carbide Manufacturer,Calcium Carbide For Export
Henan Shunbang Chemical Industry CO.,Ltd , https://www.sbpolymer.com